Literature DB >> 17709039

Diagnosis and treatment of obscure GI bleeding at double balloon endoscopy.

Naoki Ohmiya1, Tomonori Yano, Hironori Yamamoto, Daigo Arakawa, Masanao Nakamura, Wataru Honda, Akihiro Itoh, Yoshiki Hirooka, Yasumasa Niwa, Osamu Maeda, Takafumi Ando, Tsuneyoshi Yao, Toshiyuki Matsui, Mitsuo Iida, Shinji Tanaka, Tsutomu Chiba, Choitsu Sakamoto, Kentaro Sugano, Hidemi Goto.   

Abstract

BACKGROUND: Double balloon endoscopy (DBE) and videocapsule endoscopy (VCE) have been useful in managing obscure GI bleeding (OGIB).
OBJECTIVE: This study evaluated the usefulness of DBE for diagnosis, treatment, and prognosis of OGIB and compared diagnostic yield between DBE and VCE in Japan.
METHODS: Detection rates of abnormalities and diagnostic yields between VCE and DBE were compared in 74 patients at 5 centers. Of 244 patients who underwent DBE at Nagoya University Hospital, 130 (53%) with OGIB were enrolled for investigation of therapeutic procedures.
SETTING: Seven Japanese medical centers. PATIENTS: Of 1034 patients who underwent DBE between September 2000 and December 2005 at 7 medical centers, 479 (46%) with OGIB were enrolled.
RESULTS: Overall diagnostic yield of DBE for OGIB was 277 of 479 (58%). In patients with overt-ongoing bleeding, overt-previous bleeding of sporadic type, overt-previous bleeding of first attack only, occult bleeding with continuous positive fecal occult blood test (FOBT), or occult bleeding with 1 positive FOBT with iron deficiency anemia, diagnostic yield was 24 of 31 (77%), 179 of 310 (58%), 34 of 72 (47%), 24 of 35 (71%), and 56 of 93 (60%), respectively. Regarding positive findings in 277 patients, ulcers or erosions (53%) were the most frequent, followed by angiodysplasia (23%), tumors or polyps (22%), and diverticula (4%). Diagnoses in these patients were as follows: chronic inflammatory diseases (24%), vascular diseases (24%), tumor or polyps (21%), drug or radiation injury (7%), other small-bowel diseases (7%), upper GI diseases (9%), colorectal diseases (9%), and biliary disease (0.4%). Small-bowel diseases were confirmed in 226 patients (47%). Comparison of overall detection rate of abnormalities in the small bowel between VCE (65%) and DBE (53%) was not significantly different, nor was that of overall diagnostic yield between VCE (50%) and DBE (53%). Eight acute pancreatitis and 4 perforation episodes occurred with no mortalities at DBE. Of 130 patients at Nagoya University Hospital, 78 (60%) were diagnosed with small-bowel diseases and underwent treatments as follows: medication or observation only (n = 30), enteroscopic therapies (electrocoagulation in 21, clipping in 4, and polypectomy in 3), and surgery (n = 22). Small-bowel vascular diseases were more prone to rebleeding than small-bowel nonvascular diseases in patients without surgical treatment at a median follow-up of 423 days.
CONCLUSIONS: DBE was relatively safe and useful for diagnosis and treatment of OGIB. A spectrum of small-bowel diseases presenting with OGIB in Japan may be distinct from that in the Western world.

Entities:  

Mesh:

Year:  2007        PMID: 17709039     DOI: 10.1016/j.gie.2007.05.041

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  56 in total

1.  Diagnostic yield of small bowel capsule endoscopy depends on the small bowel transit time.

Authors:  Jessie Westerhof; Jan J Koornstra; Reinier A Hoedemaker; Wim J Sluiter; Jan H Kleibeuker; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

2.  Diagnosis and management of mid-gastrointestinal bleeding by double-balloon endoscopy.

Authors:  Yoshikazu Hayashi; Hironori Yamamoto; Tomonori Yano; Kentaro Sugano
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

3.  Therapeutic management options for patients with obscure gastrointestinal bleeding.

Authors:  Gursimran S Kochhar; Madhusudhan R Sanaka; John J Vargo
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

4.  Double balloon endoscopy associated pancreatitis: a description of six cases.

Authors:  Soeresh V A Jarbandhan; Stijn J B van Weyenberg; Willem M van der Veer; Dimitri G N Heine; Chris J J Mulder; Maarten A J M Jacobs
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

5.  A feasibility trial of computer-aided diagnosis for enteric lesions in capsule endoscopy.

Authors:  Tao Gan; Jun-Chao Wu; Ni-Ni Rao; Tao Chen; Bing Liu
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

6.  Abdominal surgery affects small bowel transit time and completeness of capsule endoscopy.

Authors:  Hiroki Endo; Nobuyuki Matsuhashi; Masahiko Inamori; Tomohiko Ohya; Hiroshi Iida; Hironori Mawatari; Yuichi Nozaki; Kyoko Yoneda; Tomoyuki Akiyama; Koji Fujita; Hirokazu Takahashi; Masato Yoneda; Yasunobu Abe; Noritoshi Kobayashi; Hiroyuki Kirikoshi; Kensuke Kubota; Satoru Saito; Atsushi Nakajima
Journal:  Dig Dis Sci       Date:  2008-08-22       Impact factor: 3.199

Review 7.  Double-balloon endoscopy: past, present, and future.

Authors:  Keijiro Sunada; Hironori Yamamoto
Journal:  J Gastroenterol       Date:  2009-01-22       Impact factor: 7.527

8.  Small bowel enteroscopy.

Authors:  Christopher W Teshima; Gary May
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

9.  Long-Term Outcomes in Patients with Overt Obscure Gastrointestinal Bleeding After Negative Double-Balloon Endoscopy.

Authors:  Satoshi Shinozaki; Tomonori Yano; Hirotsugu Sakamoto; Keijiro Sunada; Yoshikazu Hayashi; Hiroyuki Sato; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Dig Dis Sci       Date:  2015-07-15       Impact factor: 3.199

10.  Route selection for double-balloon endoscopy, based on capsule transit time, in obscure gastrointestinal bleeding.

Authors:  Masanao Nakamura; Naoki Ohmiya; Osamu Shirai; Hiroyuki Takenaka; Kenji Morishima; Ryoji Miyahara; Takafumi Ando; Osamu Watanabe; Hiroki Kawashima; Akihiro Itoh; Yoshiki Hirooka; Hidemi Goto
Journal:  J Gastroenterol       Date:  2010-02-03       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.